nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—ABCC10—Cytarabine—lymphatic system cancer	0.0758	0.0921	CbGbCtD
Docetaxel—TUBB8—Vincristine—lymphatic system cancer	0.0562	0.0683	CbGbCtD
Docetaxel—TUBB6—Vincristine—lymphatic system cancer	0.0562	0.0683	CbGbCtD
Docetaxel—TUBB3—Vincristine—lymphatic system cancer	0.0562	0.0683	CbGbCtD
Docetaxel—TUBB4A—Vincristine—lymphatic system cancer	0.0562	0.0683	CbGbCtD
Docetaxel—TUBB2B—Vincristine—lymphatic system cancer	0.0562	0.0683	CbGbCtD
Docetaxel—TUBB2A—Vincristine—lymphatic system cancer	0.0562	0.0683	CbGbCtD
Docetaxel—TUBB—Vincristine—lymphatic system cancer	0.0471	0.0572	CbGbCtD
Docetaxel—TUBB4B—Vincristine—lymphatic system cancer	0.0471	0.0572	CbGbCtD
Docetaxel—TUBB1—Vincristine—lymphatic system cancer	0.0471	0.0572	CbGbCtD
Docetaxel—ABCC10—Vincristine—lymphatic system cancer	0.0359	0.0437	CbGbCtD
Docetaxel—CYP1B1—Mitoxantrone—lymphatic system cancer	0.0284	0.0345	CbGbCtD
Docetaxel—ABCC10—Methotrexate—lymphatic system cancer	0.0218	0.0264	CbGbCtD
Docetaxel—ABCC1—Mitoxantrone—lymphatic system cancer	0.0202	0.0245	CbGbCtD
Docetaxel—ABCG2—Teniposide—lymphatic system cancer	0.0193	0.0234	CbGbCtD
Docetaxel—ABCC1—Vincristine—lymphatic system cancer	0.0139	0.0169	CbGbCtD
Docetaxel—ABCG2—Mitoxantrone—lymphatic system cancer	0.0135	0.0164	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—lymphatic system cancer	0.0122	0.0148	CbGbCtD
Docetaxel—SLC22A7—Methotrexate—lymphatic system cancer	0.0107	0.013	CbGbCtD
Docetaxel—CYP3A5—Teniposide—lymphatic system cancer	0.0107	0.013	CbGbCtD
Docetaxel—ABCC2—Vincristine—lymphatic system cancer	0.0103	0.0125	CbGbCtD
Docetaxel—ABCG2—Vincristine—lymphatic system cancer	0.00929	0.0113	CbGbCtD
Docetaxel—ABCC1—Methotrexate—lymphatic system cancer	0.0084	0.0102	CbGbCtD
Docetaxel—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.00686	0.00833	CbGbCtD
Docetaxel—CYP3A7—Vincristine—lymphatic system cancer	0.00686	0.00833	CbGbCtD
Docetaxel—ABCC2—Methotrexate—lymphatic system cancer	0.00622	0.00756	CbGbCtD
Docetaxel—ABCG2—Methotrexate—lymphatic system cancer	0.00562	0.00683	CbGbCtD
Docetaxel—CYP3A5—Vincristine—lymphatic system cancer	0.00515	0.00625	CbGbCtD
Docetaxel—ABCB1—Mitoxantrone—lymphatic system cancer	0.00487	0.00591	CbGbCtD
Docetaxel—CYP3A4—Cytarabine—lymphatic system cancer	0.00423	0.00514	CbGbCtD
Docetaxel—CYP3A4—Teniposide—lymphatic system cancer	0.00417	0.00506	CbGbCtD
Docetaxel—ABCB1—Vincristine—lymphatic system cancer	0.00335	0.00407	CbGbCtD
Docetaxel—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00292	0.00354	CbGbCtD
Docetaxel—ABCB1—Methotrexate—lymphatic system cancer	0.00203	0.00246	CbGbCtD
Docetaxel—CYP3A4—Vincristine—lymphatic system cancer	0.00201	0.00244	CbGbCtD
Docetaxel—KIF11—Clofarabine—Fludarabine—lymphatic system cancer	0.00064	0.155	CbGdCrCtD
Docetaxel—KIF11—Vinblastine—Vincristine—lymphatic system cancer	0.000629	0.153	CbGdCrCtD
Docetaxel—KIF11—Clofarabine—Cytarabine—lymphatic system cancer	0.000604	0.147	CbGdCrCtD
Docetaxel—KIF11—Gemcitabine—Cytarabine—lymphatic system cancer	0.00056	0.136	CbGdCrCtD
Docetaxel—KIF11—Cytarabine—Fludarabine—lymphatic system cancer	0.000545	0.132	CbGdCrCtD
Docetaxel—TUBB6—Zalcitabine—Cytarabine—lymphatic system cancer	0.000459	0.112	CbGdCrCtD
Docetaxel—TUBB—Azacitidine—Fludarabine—lymphatic system cancer	0.000247	0.0601	CbGdCrCtD
Docetaxel—TUBB—Azacitidine—Cytarabine—lymphatic system cancer	0.000234	0.0568	CbGdCrCtD
Docetaxel—Pruritus—Teniposide—lymphatic system cancer	0.000153	0.000885	CcSEcCtD
Docetaxel—Arrhythmia—Carmustine—lymphatic system cancer	0.000153	0.000885	CcSEcCtD
Docetaxel—Leukopenia—Bleomycin—lymphatic system cancer	0.000153	0.000884	CcSEcCtD
Docetaxel—Cardiac disorder—Vincristine—lymphatic system cancer	0.000152	0.000878	CcSEcCtD
Docetaxel—Alopecia—Carmustine—lymphatic system cancer	0.000151	0.000875	CcSEcCtD
Docetaxel—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000151	0.000872	CcSEcCtD
Docetaxel—Body temperature increased—Fludarabine—lymphatic system cancer	0.00015	0.000869	CcSEcCtD
Docetaxel—Mental disorder—Carmustine—lymphatic system cancer	0.00015	0.000868	CcSEcCtD
Docetaxel—Erythema—Carmustine—lymphatic system cancer	0.000149	0.000862	CcSEcCtD
Docetaxel—Malnutrition—Carmustine—lymphatic system cancer	0.000149	0.000862	CcSEcCtD
Docetaxel—Cough—Bleomycin—lymphatic system cancer	0.000149	0.000862	CcSEcCtD
Docetaxel—Angiopathy—Vincristine—lymphatic system cancer	0.000148	0.000858	CcSEcCtD
Docetaxel—Diarrhoea—Teniposide—lymphatic system cancer	0.000148	0.000856	CcSEcCtD
Docetaxel—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000147	0.000852	CcSEcCtD
Docetaxel—Chest pain—Bleomycin—lymphatic system cancer	0.000145	0.000841	CcSEcCtD
Docetaxel—Myalgia—Bleomycin—lymphatic system cancer	0.000145	0.000841	CcSEcCtD
Docetaxel—Alopecia—Vincristine—lymphatic system cancer	0.000144	0.000836	CcSEcCtD
Docetaxel—Back pain—Carmustine—lymphatic system cancer	0.000144	0.000834	CcSEcCtD
Docetaxel—Mental disorder—Vincristine—lymphatic system cancer	0.000143	0.000829	CcSEcCtD
Docetaxel—Chills—Mitoxantrone—lymphatic system cancer	0.000143	0.000826	CcSEcCtD
Docetaxel—Neoplasm—Methotrexate—lymphatic system cancer	0.000143	0.000826	CcSEcCtD
Docetaxel—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000142	0.000823	CcSEcCtD
Docetaxel—Alopecia—Mitoxantrone—lymphatic system cancer	0.000141	0.000814	CcSEcCtD
Docetaxel—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00014	0.000813	CcSEcCtD
Docetaxel—Confusional state—Bleomycin—lymphatic system cancer	0.00014	0.000813	CcSEcCtD
Docetaxel—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00014	0.00081	CcSEcCtD
Docetaxel—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000139	0.000806	CcSEcCtD
Docetaxel—Oedema—Bleomycin—lymphatic system cancer	0.000139	0.000806	CcSEcCtD
Docetaxel—Erythema—Mitoxantrone—lymphatic system cancer	0.000138	0.000802	CcSEcCtD
Docetaxel—Infection—Bleomycin—lymphatic system cancer	0.000138	0.000801	CcSEcCtD
Docetaxel—Anaemia—Carmustine—lymphatic system cancer	0.000138	0.000797	CcSEcCtD
Docetaxel—Back pain—Vincristine—lymphatic system cancer	0.000138	0.000796	CcSEcCtD
Docetaxel—Vomiting—Teniposide—lymphatic system cancer	0.000137	0.000796	CcSEcCtD
Docetaxel—Sepsis—Methotrexate—lymphatic system cancer	0.000137	0.000793	CcSEcCtD
Docetaxel—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000136	0.00079	CcSEcCtD
Docetaxel—Asthenia—Fludarabine—lymphatic system cancer	0.000136	0.000789	CcSEcCtD
Docetaxel—Rash—Teniposide—lymphatic system cancer	0.000136	0.000789	CcSEcCtD
Docetaxel—Dermatitis—Teniposide—lymphatic system cancer	0.000136	0.000788	CcSEcCtD
Docetaxel—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000136	0.000785	CcSEcCtD
Docetaxel—Headache—Teniposide—lymphatic system cancer	0.000135	0.000784	CcSEcCtD
Docetaxel—Pruritus—Fludarabine—lymphatic system cancer	0.000134	0.000778	CcSEcCtD
Docetaxel—Back pain—Mitoxantrone—lymphatic system cancer	0.000134	0.000776	CcSEcCtD
Docetaxel—Leukopenia—Carmustine—lymphatic system cancer	0.000133	0.000772	CcSEcCtD
Docetaxel—Anorexia—Bleomycin—lymphatic system cancer	0.000133	0.000769	CcSEcCtD
Docetaxel—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000132	0.000766	CcSEcCtD
Docetaxel—Anaemia—Vincristine—lymphatic system cancer	0.000131	0.000761	CcSEcCtD
Docetaxel—Hypotension—Bleomycin—lymphatic system cancer	0.00013	0.000753	CcSEcCtD
Docetaxel—Diarrhoea—Fludarabine—lymphatic system cancer	0.00013	0.000752	CcSEcCtD
Docetaxel—Convulsion—Carmustine—lymphatic system cancer	0.000129	0.000747	CcSEcCtD
Docetaxel—Hypertension—Carmustine—lymphatic system cancer	0.000129	0.000745	CcSEcCtD
Docetaxel—Nausea—Teniposide—lymphatic system cancer	0.000128	0.000743	CcSEcCtD
Docetaxel—Anaemia—Mitoxantrone—lymphatic system cancer	0.000128	0.000741	CcSEcCtD
Docetaxel—Hepatic failure—Methotrexate—lymphatic system cancer	0.000127	0.000738	CcSEcCtD
Docetaxel—Leukopenia—Vincristine—lymphatic system cancer	0.000127	0.000737	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000127	0.000735	CcSEcCtD
Docetaxel—Chest pain—Carmustine—lymphatic system cancer	0.000127	0.000734	CcSEcCtD
Docetaxel—Myalgia—Carmustine—lymphatic system cancer	0.000127	0.000734	CcSEcCtD
Docetaxel—Paraesthesia—Bleomycin—lymphatic system cancer	0.000125	0.000724	CcSEcCtD
Docetaxel—Dyspnoea—Bleomycin—lymphatic system cancer	0.000124	0.000719	CcSEcCtD
Docetaxel—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000124	0.000718	CcSEcCtD
Docetaxel—Convulsion—Vincristine—lymphatic system cancer	0.000123	0.000713	CcSEcCtD
Docetaxel—Hypertension—Vincristine—lymphatic system cancer	0.000123	0.000711	CcSEcCtD
Docetaxel—Confusional state—Carmustine—lymphatic system cancer	0.000123	0.00071	CcSEcCtD
Docetaxel—Oedema—Carmustine—lymphatic system cancer	0.000122	0.000704	CcSEcCtD
Docetaxel—Decreased appetite—Bleomycin—lymphatic system cancer	0.000121	0.000701	CcSEcCtD
Docetaxel—Myalgia—Vincristine—lymphatic system cancer	0.000121	0.000701	CcSEcCtD
Docetaxel—Visual disturbance—Methotrexate—lymphatic system cancer	0.000121	0.0007	CcSEcCtD
Docetaxel—Cough—Mitoxantrone—lymphatic system cancer	0.000121	0.0007	CcSEcCtD
Docetaxel—Infection—Carmustine—lymphatic system cancer	0.000121	0.000699	CcSEcCtD
Docetaxel—Vomiting—Fludarabine—lymphatic system cancer	0.000121	0.000699	CcSEcCtD
Docetaxel—Convulsion—Mitoxantrone—lymphatic system cancer	0.00012	0.000695	CcSEcCtD
Docetaxel—Rash—Fludarabine—lymphatic system cancer	0.00012	0.000693	CcSEcCtD
Docetaxel—Dermatitis—Fludarabine—lymphatic system cancer	0.00012	0.000693	CcSEcCtD
Docetaxel—Hypertension—Mitoxantrone—lymphatic system cancer	0.00012	0.000692	CcSEcCtD
Docetaxel—Pain—Bleomycin—lymphatic system cancer	0.000119	0.00069	CcSEcCtD
Docetaxel—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000119	0.000689	CcSEcCtD
Docetaxel—Headache—Fludarabine—lymphatic system cancer	0.000119	0.000689	CcSEcCtD
Docetaxel—Tachycardia—Carmustine—lymphatic system cancer	0.000119	0.000687	CcSEcCtD
Docetaxel—Chest pain—Mitoxantrone—lymphatic system cancer	0.000118	0.000683	CcSEcCtD
Docetaxel—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000118	0.000683	CcSEcCtD
Docetaxel—Myalgia—Mitoxantrone—lymphatic system cancer	0.000118	0.000683	CcSEcCtD
Docetaxel—Lethargy—Methotrexate—lymphatic system cancer	0.000117	0.000677	CcSEcCtD
Docetaxel—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000116	0.000672	CcSEcCtD
Docetaxel—Oedema—Vincristine—lymphatic system cancer	0.000116	0.000672	CcSEcCtD
Docetaxel—Anorexia—Carmustine—lymphatic system cancer	0.000116	0.000671	CcSEcCtD
Docetaxel—Infection—Vincristine—lymphatic system cancer	0.000115	0.000668	CcSEcCtD
Docetaxel—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000115	0.000664	CcSEcCtD
Docetaxel—Confusional state—Mitoxantrone—lymphatic system cancer	0.000114	0.00066	CcSEcCtD
Docetaxel—Nervous system disorder—Vincristine—lymphatic system cancer	0.000114	0.000659	CcSEcCtD
Docetaxel—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000114	0.000658	CcSEcCtD
Docetaxel—Hypotension—Carmustine—lymphatic system cancer	0.000114	0.000658	CcSEcCtD
Docetaxel—Oedema—Mitoxantrone—lymphatic system cancer	0.000113	0.000654	CcSEcCtD
Docetaxel—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000113	0.000654	CcSEcCtD
Docetaxel—Nausea—Fludarabine—lymphatic system cancer	0.000113	0.000653	CcSEcCtD
Docetaxel—Infection—Mitoxantrone—lymphatic system cancer	0.000112	0.00065	CcSEcCtD
Docetaxel—Shock—Mitoxantrone—lymphatic system cancer	0.000111	0.000644	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000111	0.000641	CcSEcCtD
Docetaxel—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000111	0.000641	CcSEcCtD
Docetaxel—Anorexia—Vincristine—lymphatic system cancer	0.000111	0.00064	CcSEcCtD
Docetaxel—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00011	0.000639	CcSEcCtD
Docetaxel—Body temperature increased—Bleomycin—lymphatic system cancer	0.00011	0.000637	CcSEcCtD
Docetaxel—Insomnia—Carmustine—lymphatic system cancer	0.00011	0.000637	CcSEcCtD
Docetaxel—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00011	0.000636	CcSEcCtD
Docetaxel—Paraesthesia—Carmustine—lymphatic system cancer	0.000109	0.000632	CcSEcCtD
Docetaxel—Hypotension—Vincristine—lymphatic system cancer	0.000108	0.000628	CcSEcCtD
Docetaxel—Dyspnoea—Carmustine—lymphatic system cancer	0.000108	0.000628	CcSEcCtD
Docetaxel—Somnolence—Carmustine—lymphatic system cancer	0.000108	0.000626	CcSEcCtD
Docetaxel—Anorexia—Mitoxantrone—lymphatic system cancer	0.000108	0.000624	CcSEcCtD
Docetaxel—Ataxia—Methotrexate—lymphatic system cancer	0.000108	0.000624	CcSEcCtD
Docetaxel—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000106	0.000612	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000106	0.000612	CcSEcCtD
Docetaxel—Decreased appetite—Carmustine—lymphatic system cancer	0.000106	0.000612	CcSEcCtD
Docetaxel—Hypotension—Mitoxantrone—lymphatic system cancer	0.000106	0.000611	CcSEcCtD
Docetaxel—Insomnia—Vincristine—lymphatic system cancer	0.000105	0.000608	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000105	0.000608	CcSEcCtD
Docetaxel—Paraesthesia—Vincristine—lymphatic system cancer	0.000104	0.000603	CcSEcCtD
Docetaxel—Constipation—Carmustine—lymphatic system cancer	0.000104	0.000602	CcSEcCtD
Docetaxel—Pain—Carmustine—lymphatic system cancer	0.000104	0.000602	CcSEcCtD
Docetaxel—Breast disorder—Methotrexate—lymphatic system cancer	0.000104	0.000599	CcSEcCtD
Docetaxel—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000103	0.000597	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000103	0.000596	CcSEcCtD
Docetaxel—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000103	0.000594	CcSEcCtD
Docetaxel—TUBB6—Azacitidine—Fludarabine—lymphatic system cancer	0.000102	0.0248	CbGdCrCtD
Docetaxel—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000101	0.000588	CcSEcCtD
Docetaxel—Decreased appetite—Vincristine—lymphatic system cancer	0.000101	0.000584	CcSEcCtD
Docetaxel—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000101	0.000583	CcSEcCtD
Docetaxel—Somnolence—Mitoxantrone—lymphatic system cancer	0.0001	0.000582	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0001	0.00058	CcSEcCtD
Docetaxel—Feeling abnormal—Carmustine—lymphatic system cancer	0.0001	0.00058	CcSEcCtD
Docetaxel—Fatigue—Vincristine—lymphatic system cancer	0.0001	0.000579	CcSEcCtD
Docetaxel—Asthenia—Bleomycin—lymphatic system cancer	9.99e-05	0.000579	CcSEcCtD
Docetaxel—Dyspepsia—Mitoxantrone—lymphatic system cancer	9.95e-05	0.000576	CcSEcCtD
Docetaxel—Gastrointestinal pain—Carmustine—lymphatic system cancer	9.94e-05	0.000576	CcSEcCtD
Docetaxel—Pain—Vincristine—lymphatic system cancer	9.92e-05	0.000575	CcSEcCtD
Docetaxel—Constipation—Vincristine—lymphatic system cancer	9.92e-05	0.000575	CcSEcCtD
Docetaxel—Pruritus—Bleomycin—lymphatic system cancer	9.85e-05	0.00057	CcSEcCtD
Docetaxel—Decreased appetite—Mitoxantrone—lymphatic system cancer	9.82e-05	0.000569	CcSEcCtD
Docetaxel—Fatigue—Mitoxantrone—lymphatic system cancer	9.74e-05	0.000564	CcSEcCtD
Docetaxel—Constipation—Mitoxantrone—lymphatic system cancer	9.66e-05	0.00056	CcSEcCtD
Docetaxel—Pain—Mitoxantrone—lymphatic system cancer	9.66e-05	0.00056	CcSEcCtD
Docetaxel—TUBB6—Azacitidine—Cytarabine—lymphatic system cancer	9.65e-05	0.0234	CbGdCrCtD
Docetaxel—Body temperature increased—Carmustine—lymphatic system cancer	9.61e-05	0.000556	CcSEcCtD
Docetaxel—Abdominal pain—Carmustine—lymphatic system cancer	9.61e-05	0.000556	CcSEcCtD
Docetaxel—Gastrointestinal pain—Vincristine—lymphatic system cancer	9.49e-05	0.000549	CcSEcCtD
Docetaxel—Pancytopenia—Methotrexate—lymphatic system cancer	9.4e-05	0.000544	CcSEcCtD
Docetaxel—Feeling abnormal—Mitoxantrone—lymphatic system cancer	9.31e-05	0.000539	CcSEcCtD
Docetaxel—Neutropenia—Methotrexate—lymphatic system cancer	9.26e-05	0.000536	CcSEcCtD
Docetaxel—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	9.24e-05	0.000535	CcSEcCtD
Docetaxel—Body temperature increased—Vincristine—lymphatic system cancer	9.17e-05	0.000531	CcSEcCtD
Docetaxel—Abdominal pain—Vincristine—lymphatic system cancer	9.17e-05	0.000531	CcSEcCtD
Docetaxel—Hypersensitivity—Carmustine—lymphatic system cancer	8.96e-05	0.000519	CcSEcCtD
Docetaxel—Abdominal pain—Mitoxantrone—lymphatic system cancer	8.93e-05	0.000517	CcSEcCtD
Docetaxel—Body temperature increased—Mitoxantrone—lymphatic system cancer	8.93e-05	0.000517	CcSEcCtD
Docetaxel—Pneumonia—Methotrexate—lymphatic system cancer	8.88e-05	0.000514	CcSEcCtD
Docetaxel—Vomiting—Bleomycin—lymphatic system cancer	8.85e-05	0.000513	CcSEcCtD
Docetaxel—Infestation—Methotrexate—lymphatic system cancer	8.83e-05	0.000511	CcSEcCtD
Docetaxel—Infestation NOS—Methotrexate—lymphatic system cancer	8.83e-05	0.000511	CcSEcCtD
Docetaxel—Rash—Bleomycin—lymphatic system cancer	8.78e-05	0.000508	CcSEcCtD
Docetaxel—Dermatitis—Bleomycin—lymphatic system cancer	8.77e-05	0.000508	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	8.75e-05	0.000507	CcSEcCtD
Docetaxel—Asthenia—Carmustine—lymphatic system cancer	8.72e-05	0.000505	CcSEcCtD
Docetaxel—Renal failure—Methotrexate—lymphatic system cancer	8.68e-05	0.000502	CcSEcCtD
Docetaxel—Stomatitis—Methotrexate—lymphatic system cancer	8.6e-05	0.000498	CcSEcCtD
Docetaxel—Conjunctivitis—Methotrexate—lymphatic system cancer	8.58e-05	0.000497	CcSEcCtD
Docetaxel—Hypersensitivity—Vincristine—lymphatic system cancer	8.55e-05	0.000495	CcSEcCtD
Docetaxel—Hepatobiliary disease—Methotrexate—lymphatic system cancer	8.35e-05	0.000483	CcSEcCtD
Docetaxel—Epistaxis—Methotrexate—lymphatic system cancer	8.33e-05	0.000482	CcSEcCtD
Docetaxel—Hypersensitivity—Mitoxantrone—lymphatic system cancer	8.33e-05	0.000482	CcSEcCtD
Docetaxel—Asthenia—Vincristine—lymphatic system cancer	8.32e-05	0.000482	CcSEcCtD
Docetaxel—Diarrhoea—Carmustine—lymphatic system cancer	8.32e-05	0.000482	CcSEcCtD
Docetaxel—Nausea—Bleomycin—lymphatic system cancer	8.27e-05	0.000479	CcSEcCtD
Docetaxel—Agranulocytosis—Methotrexate—lymphatic system cancer	8.24e-05	0.000477	CcSEcCtD
Docetaxel—Asthenia—Mitoxantrone—lymphatic system cancer	8.11e-05	0.000469	CcSEcCtD
Docetaxel—Dizziness—Carmustine—lymphatic system cancer	8.04e-05	0.000465	CcSEcCtD
Docetaxel—Haemoglobin—Methotrexate—lymphatic system cancer	7.96e-05	0.000461	CcSEcCtD
Docetaxel—Diarrhoea—Vincristine—lymphatic system cancer	7.94e-05	0.00046	CcSEcCtD
Docetaxel—Haemorrhage—Methotrexate—lymphatic system cancer	7.92e-05	0.000459	CcSEcCtD
Docetaxel—Hepatitis—Methotrexate—lymphatic system cancer	7.92e-05	0.000459	CcSEcCtD
Docetaxel—Pharyngitis—Methotrexate—lymphatic system cancer	7.86e-05	0.000455	CcSEcCtD
Docetaxel—Urinary tract disorder—Methotrexate—lymphatic system cancer	7.83e-05	0.000453	CcSEcCtD
Docetaxel—Urethral disorder—Methotrexate—lymphatic system cancer	7.77e-05	0.00045	CcSEcCtD
Docetaxel—Diarrhoea—Mitoxantrone—lymphatic system cancer	7.73e-05	0.000448	CcSEcCtD
Docetaxel—Vomiting—Carmustine—lymphatic system cancer	7.73e-05	0.000448	CcSEcCtD
Docetaxel—Dizziness—Vincristine—lymphatic system cancer	7.67e-05	0.000444	CcSEcCtD
Docetaxel—Rash—Carmustine—lymphatic system cancer	7.66e-05	0.000444	CcSEcCtD
Docetaxel—Dermatitis—Carmustine—lymphatic system cancer	7.66e-05	0.000443	CcSEcCtD
Docetaxel—Visual impairment—Methotrexate—lymphatic system cancer	7.64e-05	0.000442	CcSEcCtD
Docetaxel—Headache—Carmustine—lymphatic system cancer	7.61e-05	0.000441	CcSEcCtD
Docetaxel—Erythema multiforme—Methotrexate—lymphatic system cancer	7.49e-05	0.000434	CcSEcCtD
Docetaxel—Eye disorder—Methotrexate—lymphatic system cancer	7.41e-05	0.000429	CcSEcCtD
Docetaxel—Vomiting—Vincristine—lymphatic system cancer	7.38e-05	0.000427	CcSEcCtD
Docetaxel—Cardiac disorder—Methotrexate—lymphatic system cancer	7.35e-05	0.000426	CcSEcCtD
Docetaxel—Rash—Vincristine—lymphatic system cancer	7.32e-05	0.000424	CcSEcCtD
Docetaxel—Dermatitis—Vincristine—lymphatic system cancer	7.31e-05	0.000423	CcSEcCtD
Docetaxel—Headache—Vincristine—lymphatic system cancer	7.27e-05	0.000421	CcSEcCtD
Docetaxel—Nausea—Carmustine—lymphatic system cancer	7.22e-05	0.000418	CcSEcCtD
Docetaxel—Angiopathy—Methotrexate—lymphatic system cancer	7.19e-05	0.000416	CcSEcCtD
Docetaxel—Vomiting—Mitoxantrone—lymphatic system cancer	7.18e-05	0.000416	CcSEcCtD
Docetaxel—Immune system disorder—Methotrexate—lymphatic system cancer	7.16e-05	0.000414	CcSEcCtD
Docetaxel—Mediastinal disorder—Methotrexate—lymphatic system cancer	7.14e-05	0.000414	CcSEcCtD
Docetaxel—Rash—Mitoxantrone—lymphatic system cancer	7.12e-05	0.000413	CcSEcCtD
Docetaxel—Dermatitis—Mitoxantrone—lymphatic system cancer	7.12e-05	0.000412	CcSEcCtD
Docetaxel—Chills—Methotrexate—lymphatic system cancer	7.11e-05	0.000412	CcSEcCtD
Docetaxel—Headache—Mitoxantrone—lymphatic system cancer	7.08e-05	0.00041	CcSEcCtD
Docetaxel—Alopecia—Methotrexate—lymphatic system cancer	7e-05	0.000406	CcSEcCtD
Docetaxel—Mental disorder—Methotrexate—lymphatic system cancer	6.94e-05	0.000402	CcSEcCtD
Docetaxel—Erythema—Methotrexate—lymphatic system cancer	6.9e-05	0.000399	CcSEcCtD
Docetaxel—Malnutrition—Methotrexate—lymphatic system cancer	6.9e-05	0.000399	CcSEcCtD
Docetaxel—Nausea—Vincristine—lymphatic system cancer	6.89e-05	0.000399	CcSEcCtD
Docetaxel—Dysgeusia—Methotrexate—lymphatic system cancer	6.76e-05	0.000391	CcSEcCtD
Docetaxel—Nausea—Mitoxantrone—lymphatic system cancer	6.71e-05	0.000389	CcSEcCtD
Docetaxel—Back pain—Methotrexate—lymphatic system cancer	6.67e-05	0.000386	CcSEcCtD
Docetaxel—Anaemia—Methotrexate—lymphatic system cancer	6.38e-05	0.000369	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—lymphatic system cancer	6.17e-05	0.000358	CcSEcCtD
Docetaxel—Cough—Methotrexate—lymphatic system cancer	6.02e-05	0.000349	CcSEcCtD
Docetaxel—Convulsion—Methotrexate—lymphatic system cancer	5.98e-05	0.000346	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—lymphatic system cancer	5.87e-05	0.00034	CcSEcCtD
Docetaxel—Myalgia—Methotrexate—lymphatic system cancer	5.87e-05	0.00034	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—lymphatic system cancer	5.87e-05	0.00034	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	5.83e-05	0.000338	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—lymphatic system cancer	5.68e-05	0.000329	CcSEcCtD
Docetaxel—Anaphylactic shock—Methotrexate—lymphatic system cancer	5.63e-05	0.000326	CcSEcCtD
Docetaxel—Infection—Methotrexate—lymphatic system cancer	5.59e-05	0.000324	CcSEcCtD
Docetaxel—Nervous system disorder—Methotrexate—lymphatic system cancer	5.52e-05	0.00032	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—lymphatic system cancer	5.51e-05	0.000319	CcSEcCtD
Docetaxel—Skin disorder—Methotrexate—lymphatic system cancer	5.47e-05	0.000317	CcSEcCtD
Docetaxel—Anorexia—Methotrexate—lymphatic system cancer	5.37e-05	0.000311	CcSEcCtD
Docetaxel—Hypotension—Methotrexate—lymphatic system cancer	5.26e-05	0.000305	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	5.13e-05	0.000297	CcSEcCtD
Docetaxel—Insomnia—Methotrexate—lymphatic system cancer	5.09e-05	0.000295	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—lymphatic system cancer	5.06e-05	0.000293	CcSEcCtD
Docetaxel—Dyspnoea—Methotrexate—lymphatic system cancer	5.02e-05	0.000291	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—lymphatic system cancer	5.01e-05	0.00029	CcSEcCtD
Docetaxel—Dyspepsia—Methotrexate—lymphatic system cancer	4.96e-05	0.000287	CcSEcCtD
Docetaxel—Decreased appetite—Methotrexate—lymphatic system cancer	4.89e-05	0.000283	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	4.86e-05	0.000281	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—lymphatic system cancer	4.85e-05	0.000281	CcSEcCtD
Docetaxel—Pain—Methotrexate—lymphatic system cancer	4.81e-05	0.000279	CcSEcCtD
Docetaxel—Feeling abnormal—Methotrexate—lymphatic system cancer	4.64e-05	0.000269	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methotrexate—lymphatic system cancer	4.6e-05	0.000267	CcSEcCtD
Docetaxel—Body temperature increased—Methotrexate—lymphatic system cancer	4.45e-05	0.000258	CcSEcCtD
Docetaxel—Abdominal pain—Methotrexate—lymphatic system cancer	4.45e-05	0.000258	CcSEcCtD
Docetaxel—Hypersensitivity—Methotrexate—lymphatic system cancer	4.15e-05	0.00024	CcSEcCtD
Docetaxel—Asthenia—Methotrexate—lymphatic system cancer	4.04e-05	0.000234	CcSEcCtD
Docetaxel—Pruritus—Methotrexate—lymphatic system cancer	3.98e-05	0.000231	CcSEcCtD
Docetaxel—Diarrhoea—Methotrexate—lymphatic system cancer	3.85e-05	0.000223	CcSEcCtD
Docetaxel—Dizziness—Methotrexate—lymphatic system cancer	3.72e-05	0.000216	CcSEcCtD
Docetaxel—Vomiting—Methotrexate—lymphatic system cancer	3.58e-05	0.000207	CcSEcCtD
Docetaxel—Rash—Methotrexate—lymphatic system cancer	3.55e-05	0.000206	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—lymphatic system cancer	3.55e-05	0.000205	CcSEcCtD
Docetaxel—Headache—Methotrexate—lymphatic system cancer	3.53e-05	0.000204	CcSEcCtD
Docetaxel—Nausea—Methotrexate—lymphatic system cancer	3.34e-05	0.000194	CcSEcCtD
